Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.60 |
| ▸ | RAD52 | P43351 | 2/20 | 0.58 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980413 | 0.89 | SLC2A1 (0.62) | POLBTLR9FLT3SLC2A1 | |
| SCHEMBL3973275 | 0.87 | RAD52 (0.69) | POLBTLR9RAD52SMARCA2FLT3 | |
| SCHEMBL3974635 | 0.85 | ACP1 (0.58) | POLBFLT3ACP1SLC2A1MAPK1 | |
| SCHEMBL3974901 | 0.84 | SLC2A1 (0.72) | POLBFLT3SLC2A1 | |
| SCHEMBL14758284 | 0.82 | POLB (0.86) | POLBTLR9RAD52SMARCA2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL7437628 | 0.81 | PDE5A (0.69) | POLBTLR9FLT3ACP1ALDH1A1 | |
| SCHEMBL3973396 | 0.81 | TLR9 (0.56) | POLBTLR9RAD52SMARCA2ACP1 | |
| SCHEMBL3977603 | 0.79 | PDE5A (0.70) | ALDH1A1MAPK1 | |
| SCHEMBL3975155 | 0.78 | POLB (0.46) | POLBFLT3MAPK1 | |
| SCHEMBL3980578 | 0.78 | MAPK1 (0.58) | TLR9FLT3ACP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2004030672-A1 | USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | POLB 4723/4885TLR9 4215/4885RAD52 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.